Iparomilimab
Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2/3Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
59 Active assets in the Neoadjuvant Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Seventh Medical Center of PLA General Hospital | Phase 4 | BB |
rc48-adc First Affiliated Hospital of Guangxi Medical University | Phase 4 | BB |
S-1 Tao Zhang | Phase 4 | B |
FLUOROURACILUM Azienda Unita Sanitaria Locale di Piacenza | Phase 4 | B |
Capecitabine Tao Zhang | Phase 3 | B |
View all 50 →
Same molecule, other indications
Iparomilimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →